

Southeast Asia Olmesartan Market to Hit a Sales of US\$ 491.79 Million By 2031 | Indonesia Attained Sales of US\$ 89 Mn

CHICAGO, UNITED STATES, August 29, 2023

/EINPresswire.com/ -- [Astute Analytica](#) [Southeast Asia Olmesartan Market](#) sales reached **US\$ 491.79 million** in 2022 and is projected to surpass a valuation of **US\$ 491.79 million** by 2031, growing at a **CAGR of 10.5%** during the forecast period from 2023 to 2031.

For more information, contact info@astuteanalytica.com or visit <https://www.astuteanalytica.com/request-sample/southeast-asia-olmesartan-market>

The olmesartan market in Southeast Asia has been steadily expanding in recent years due to the region's increasing prevalence of cardiovascular disease and hypertension and ongoing improvements in the region's healthcare infrastructure and medical technology.



The World Health Organization (WHO) reports that more than 25% of adults in Southeast Asia suffer from hypertension, making it one of the highest rates worldwide. A significant factor driving the demand for olmesartan in Southeast Asia is the region's rising prevalence of hypertension. Numerous causes, such as sedentary lifestyles, unhealthy eating patterns, and a fast-aging population, are the main reasons for the rising prevalence of hypertension. For instance, the WHO estimates that while the percentage of adults 60 and older was 9.8% in 2017 it will rise to 13.7% and 20.3%, respectively, by 2030 and 2050.

The population is becoming more aware of the value of preserving cardiovascular health and taking preventative measures to avoid issues related to hypertension, which is fueling market growth. For instance, according to The Global Burden of Disease Study, 40% of all fatalities in the area were caused by cardiovascular disorders. Additionally, according to projections from the World Health Organization (WHO), 17.9 million people die each year from cardiovascular diseases (CVDs), and by 2030, that number is expected to rise to 22.2 million.

In order to fight the region's expanding cardiovascular disease burden, governments, healthcare

organizations, and medical professionals are actively pushing preventive measures. This includes campaigns to spread knowledge about hypertension, encourage routine physicals, promote lifestyle changes, and emphasize the value of early intervention. In Vietnam, for example, the national plan for NCD prevention and control (2015–2025) seeks to detect 50% of people with hypertension and treat and manage at least 50% of those who have been diagnosed.

Olmesartan is the top revenue producer in the 20 mg dose segment, with sales of US\$ 123.10 million in 2022.

The 20 mg dose segment emerged as the top revenue producer, with sales of US\$ 123.10 million in 2022. The segment is likely to continue growing at a compound annual growth rate (CAGR) of 4.9% over the projected period.

The 20 mg dosage is popular for effectively managing blood pressure while minimizing side effects. Additionally, it provides a well-rounded strategy for individuals who need dosage strengths ranging from moderate to high. Due to its widespread acceptability among medical practitioners and its demonstrated efficacy in controlling hypertension, the category has maintained its dominance.

Olmesartan is the top revenue producer in the adult sector, with sales of US\$ 267.89 million in 2022.

The adult sector dominated the market in 2022, capturing revenue of US\$ 267.89 million. The segment is likely to expand at a CAGR of 4.2% during the forecast period. The demand for olmesartan in the adult market has been driven by the high prevalence of hypertension among the adult population and the expanding elderly population in the area.

As per WHO, hypertension is the single most significant leading cause of cardiovascular disease mortality in the region. 25% of adults have high blood pressure, just 1 in 3 are receiving treatment, and only 1 in 10 adults with the condition have it under control.

Indonesia is crucial to the region's olmesartan business, with sales of US\$ 89 million in 2022.

Indonesia is crucial to the region's olmesartan business. With a population of over 270 million, the nation makes a considerable financial contribution to the local economy. In 2022, the country captured around US\$ 89 million.

Numerous elements contribute to Indonesia's top ranking, including the nation's high rates of cardiovascular, hypertensive, and diabetic disorders. Statistics suggest that over 30% of adults in Indonesia suffer from hypertension, which affects a sizeable section of the country's population. Additionally, with about 10% of the population affected, diabetes has become a growing health concern. The prevalence of both diabetes and hypertension among many people drives up demand for the blood pressure medication olmesartan.

For more information, visit <https://www.astuteanalytica.com/industry-olmesartan-vietnam/>

The demand for olmesartan is anticipated to rise even further due to Indonesia's expanding healthcare infrastructure and rising cardiovascular health awareness. Furthermore, cardiovascular conditions are a major cause of death in Indonesia and are a considerable health burden. These concerning data have increased the demand for potent antihypertensive drugs like olmesartan, which is fueling the expansion of the industry in the nation.

Key Market Participants

Market participants are taking advantage of this growing demand in the region by concentrating on increasing their presence, forging strategic alliances, and adjusting their marketing strategies to meet the unique requirements of the market.

Key Market Players

- Daiichi Sankyo Company
- Pfizer
- Lupin Limited
- Zydus Cadila
- Abbott
- Glenmark Pharmaceuticals Ltd
- Alembic Pharmaceuticals limited
- Sun Pharmaceutical Industries Ltd
- Unichem Laboratories
- Cipla Ltd.
- Torrent Pharmaceuticals Ltd
- Other Prominent Players

Key Market Segments

The market is segmented by dosage form, strength, and formulation. The major segments are tablets, capsules, and oral suspension. The major strengths are 10 mg, 20 mg, and 40 mg. The major formulations are immediate release and controlled release.

Key Indications

- 10 mg
- 20 mg
- 40 mg
- Others

Key Applications

- High Blood Pressure
- Heart Failure
- Diabetic Kidney Disease
- Others

□□ □□ □□□□

- Adult
- Pediatric

□□ □□□□□□□□□□ □□□□□□

- Online
- Offline

□□ □□□□□□

- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia

□□□□□□□ □□□□□□ □□□□□ □□□ □□ □□□□□□□□ □□□□□□@-

<https://www.astuteanalytica.com/request-sample/southeast-asia-olmesartan-market>

□□□□□ □□□□□□ □□□□□□□□□□:

Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth, and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the globe.

They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of the best cost-effective, value-added package from us, should you decide to engage with us.

Aamir Beg
Astute Analytica
+1 888-429-6757

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/652577215>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.